靶向DNA损伤反应通过STING介导的T细胞激活促进小细胞肺癌抗肿瘤免疫
本研究在小细胞肺癌(SCLC)模型中显示,抑制DNA损伤反应蛋白PARP或CHK1可显著增加PD-L1的蛋白和表面表达,并增强PD-L1阻断的抗肿瘤效果及细胞毒性T细胞浸润;CD8+ T细胞清除可逆转该效应。DDR抑制激活STING/TBK1/IRF3 innate免疫通路,上调CXCL10和CCL5等趋化因子;敲低cGAS和STING可逆转联合抑制DDR与PD-L1的抗肿瘤效果。
要点
- PARP或CHK1抑制增加SCLC中PD-L1蛋白和表面表达。
- DDR抑制增强PD-L1阻断的抗肿瘤效果并增加细胞毒性T细胞浸润。
- STING/TBK1/IRF3通路及CXCL10、CCL5参与DDR抑制介导的免疫激活。
核心结论
- DDR蛋白具有此前未识别的免疫调节功能,为SCLC中联合PARP/CHK1抑制剂与免疫治疗提供依据。
- 作者认为在ICB基础上加入PARP或CHK1抑制剂可能提高SCLC患者的疗效。
- 本研究支持innate免疫STING通路在DDR介导的SCLC抗肿瘤免疫中的作用。
研究设计与样本
- 研究在多个免疫健全的SCLC体内模型中进行,采用DDR蛋白PARP和CHK1抑制。
- 通过CD8+ T细胞清除及cGAS和STING敲低实验验证机制。
主要发现
- 靶向PARP和CHK1显著增加PD-L1的蛋白和表面表达。
- PARP或CHK1抑制显著增强PD-L1阻断的抗肿瘤效果,并增加细胞毒性T细胞浸润。
- CD8+ T细胞清除逆转抗肿瘤效果,表明CD8+ T细胞在联合DDR-PD-L1阻断中的作用。
- DDR抑制激活STING/TBK1/IRF3 innate免疫通路,增加CXCL10和CCL5等趋化因子水平,诱导细胞毒性T淋巴细胞激活和功能。
- 敲低cGAS和STING成功逆转联合抑制DDR和PD-L1的抗肿瘤效果。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite recent advances in the use of immunotherapy, only a minority of patients with small cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that targeting the DNA damage response (DDR) proteins PARP and checkpoint kinase 1 (CHK1) significantly increased protein and surface expression of PD-L1. PARP or CHK1 inhibition remarkably potentiated the antitumor effect of PD-L1 blockade and augmented cytotoxic T-cell infiltration in multiple immunocompetent SCLC in vivo models. CD8+ T-cell depletion reversed the antitumor effect, demonstrating the role of CD8+ T cells in combined DDR-PD-L1 blockade in SCLC. We further demonstrate that DDR inhibition activated the STING/TBK1/IRF3 innate immune pathway, leading to increased levels of chemokines such as CXCL10 and CCL5 that induced activation and function of cytotoxic T lymphocytes. Knockdown of cGAS and STING successfully reversed the antitumor effect of combined inhibition of DDR and PD-L1. Our results define previously unrecognized innate immune pathway-mediated immunomodulatory functions of DDR proteins and provide a rationale for combining PARP/CHK1 inhibitors and immunotherapies in SCLC. SIGNIFICANCE: Our results define previously unrecognized immunomodulatory functions of DDR inhibitors and suggest that adding PARP or CHK1 inhibitors to ICB may enhance treatment efficacy in patients with SCLC. Furthermore, our study supports a role of innate immune STING pathway in DDR-mediated antitumor immunity in SCLC.See related commentary by Hiatt and MacPherson, p. 584.This article is highlighted in the In This Issue feature, p. 565.
引用
- Sen T, Rodriguez BL, Chen L, et al. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019. PMID: 30777870. doi:10.1158/2159-8290.CD-18-1020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。